Scholar Rock wins FDA approval for ISEMBYLD
Scholar Rock said the FDA approved ISEMBYLD for SMA in patients age 2 and older on an SMN2-targeted therapy, and it is starting a U.S. commercial launch.
S. Key Highlights:Original SEC Filing: Scholar Rock Holding Corp [ SRRK ] - 8-K - Sep. 14, 2026This is an AI-powered summary. It may contain inaccuracies.
Co…